A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial.
Zane LK, Yee LM, Chang TC, Sklar J, Yang G, Wen JD, Li P, Harrington R, Sims DJ, Harper K, Trent JM, LoBello JR, Szelinger S, Benson K, Zeng J, Poorman K, Xu D, Frampton GM, Pavlick DC, Miller VA, Tandon B, Swat W, Weiss L, Funari VA, Conroy JM, Prescott JL, Chandra PK, Ma C, Champion KJ, Baschkopf GX, Fesko YA, Freitas TAK, Tomlins SA, Hovelson DH, White K, Sorrells S, Tell R, Beaubier N, King D, Li L, Kelly K, Uvalic J, Meyers B, Kolhe R, Lindeman NI, Baltay M, Sholl LM, Lopategui J, Vail E, Zhang W, Telatar M, Afkhami M, Hsiao SJ, Mansukhani MM, Adams E, Jiang L; NCI-MATCH Designated Laboratories; Aldape KD, Raffeld M, Xi L; for NCI-COMPASS Team; Stehr H, Segal JP, Aisner DL, Davies KD, Brown NA, Livingston RJ, Konnick EQ, Song W, Solomon JP, Walther Z; for NCI-MATCH Designated Laboratories; McShane LM, Harris LN, Chen AP, Tsongalis GJ, Hamilton SR, Flaherty KT, O'Dwyer PJ, Conley BA, Patton DR, Iafrate AJ, Williams PM, Tricoli JV, Karlovich C.
Zane LK, et al. Among authors: lobello jr.
Clin Cancer Res. 2025 Aug 14;31(16):3512-3525. doi: 10.1158/1078-0432.CCR-24-2188.
Clin Cancer Res. 2025.
PMID: 40465838